-
1.发明公开TREATMENT OF EVOLVING BACTERIAL RESISTANCE DISEASES INCLUDING KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY FORMULATED GLUTATHIONE 审中-公开克雷伯菌肺炎的治疗介导的疾病不断发展的抗菌性使用脂质体制定谷胱甘肽
公开(公告)号：EP2956153A4
公开(公告)日：2017-03-22
申请号：EP13875036
申请日：2013-03-15
CPC分类号： A61K9/127 , A61K9/0095 , A61K9/4858 , A61K31/407 , A61K31/43 , A61K31/59 , A61K38/063 , A61K45/06 , C12Q1/06 , C12Q1/18 , G01N2800/52 , A61K2300/00
摘要： The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.
-
2.发明公开TREATMENT OF KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY FORMULATED GLUTATHIONE 有权肺炎克雷伯菌，脂质体配制的还原型谷胱甘肽治疗
公开(公告)号：EP2956131A4
公开(公告)日：2016-08-24
申请号：EP14751072
申请日：2014-02-14
CPC分类号： A61K38/063 , A61K9/0014 , A61K9/0019 , A61K9/0053 , A61K9/006 , A61K9/0095 , A61K9/127 , A61K9/4858
摘要： The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.
-
3.发明公开TREATMENT OF EVOLVING BACTERIAL RESISTANCE DISEASES INCLUDING KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY FORMULATED GLUTATHIONE 审中-公开克雷伯菌肺炎的治疗介导的疾病不断发展的抗菌性使用脂质体制定谷胱甘肽
公开(公告)号：EP2956153A1
公开(公告)日：2015-12-23
申请号：EP13875036.9
申请日：2013-03-15
CPC分类号： A61K9/127 , A61K9/0095 , A61K9/4858 , A61K31/407 , A61K31/43 , A61K31/59 , A61K38/063 , A61K45/06 , C12Q1/06 , C12Q1/18 , G01N2800/52 , Y02A50/409 , Y02A50/475 , A61K2300/00
摘要： The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.
摘要翻译： 本发明中，脂质体谷胱甘肽的组合物，最近已经显示出具有实用程序不必像在体外和体内的肺炎克雷伯菌培养物作用的抗生素如通过功效在由大倍数减少大鼠克雷伯菌的培养物中的存在以实例阐述 动物试验。 此外，由于脂质体谷胱甘肽支持了机体抵抗力，以及涉嫌利用具有直接杀伤作用，倾向以抗生素治疗降级创造更多的耐药菌株。
-
公开(公告)号：EP3324993A1
公开(公告)日：2018-05-30
申请号：EP16828549.2
申请日：2016-07-21
CPC分类号： A61K38/063 , A61K9/127 , A61K33/04 , A61K38/06 , A61K2300/00 , A61P31/14
摘要： This invention relates to a composition, the use of a composition for treatment, and a method of treatment of infection with Respiratory syncytial virus (RSV). The composition for treatment is a liposomally formulated reduced glutathione in a therapeutically effective amount to decrease the growth of respiratory syncytial virus. An oral preparation of liposomal reduced glutathione and a powdered form that can be reconstituted with sterile water or saline for intravenous administration are described.
-
5.发明授权TREATMENT OF KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY FORMULATED GLUTATHIONE 有权脂质体制剂谷胱甘肽治疗KLEBSIELLA PNEUMONIAE
公开(公告)号：EP2956131B1
公开(公告)日：2017-12-20
申请号：EP14751072.1
申请日：2014-02-14
CPC分类号： A61K38/063 , A61K9/0014 , A61K9/0019 , A61K9/0053 , A61K9/006 , A61K9/0095 , A61K9/127 , A61K9/4858
摘要： The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.
-
6.发明公开TREATMENT OF KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY FORMULATED GLUTATHIONE 有权百日咳KLEBSIELLA PNEUMONIAE MIT LIPOSOMAL FORMULIERTEM GLUTATHION
公开(公告)号：EP2956131A1
公开(公告)日：2015-12-23
申请号：EP14751072.1
申请日：2014-02-14
IPC分类号： A61K31/198 , A61K31/195 , A61K9/127
CPC分类号： A61K38/063 , A61K9/0014 , A61K9/0019 , A61K9/0053 , A61K9/006 , A61K9/0095 , A61K9/127 , A61K9/4858
摘要： The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.
摘要翻译： 本发明的组合物脂质体谷胱甘肽近来被证明具有在体外对抗肺炎克雷伯菌培养物具有抗生素作用的效用，并且在体内如通过大量倍数减少大鼠克雷伯杆菌培养物的效力所证实的 动物试验。 此外，由于脂质体谷胱甘肽抵抗身体防御以及似乎具有直接杀伤作用，因此降低对抗生素治疗产生越来越多抗性菌株的倾向。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.009 秒)
